Value, pricing & access (VPA) strategy.

Eric leads Putnam’s global Value, Pricing & Access practice of 250+ professionals across 10 offices. With 27+ years at Putnam, he specializes in market access strategy and helps clients navigate payer, healthcare system, and competitive environments

Ryan is a Partner in Putnam’s Value, Pricing & Access Practice, advising biopharma and early-stage companies on pricing and access strategy, new product strategy, and medical affairs strategy at both the portfolio and product level.

Alex advises clients at the intersection of transformative pharmacology, commercial strategy, and Value, Pricing & Access. He supports global and emerging biotech companies on pre-launch and in-line strategy across major pharma markets.

Joanne leads Putnam’s European Value, Pricing & Access practice. With 18 years’ experience, she advises biopharma from early asset planning through launch, helping clients navigate complex payer and healthcare systems to enable optimal patient access.

Scott advises clients across Value, Pricing & Access, Commercial Strategy, and Business Analytics. He has extensive global experience across vaccines, infectious disease, oncology, rare diseases, orthopedics, immunology, renal disorders, and neurology.

Hugo specializes in Value, Pricing & Access, developing pricing and contracting strategies for pharma and biotech across US and international markets. He has deep experience creating access strategies for therapies in inpatient and outpatient settings.

Since joining Putnam in 2017, Ethan has advised clients on pricing and access, opportunity assessment, competitive simulation, operating model design, and forecasting. He supports global pharma and biotech across US and international markets.

Maaz advises biopharma and life sciences clients on value, pricing and access, commercial strategy, and cross-functional initiatives. His experience spans oncology, hematology, respiratory, and advanced modalities including gene therapies.